These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD; Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343 [TBL] [Abstract][Full Text] [Related]
6. Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study. Yuan F; Wang H; Tian Y; Li Q; He L; Li N; Liu Z Lipids Health Dis; 2016 Feb; 15():20. PubMed ID: 26832365 [TBL] [Abstract][Full Text] [Related]
7. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD. Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154 [TBL] [Abstract][Full Text] [Related]
9. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. Mitrovic M; Sistilli G; Horakova O; Rossmeisl M Eur J Clin Invest; 2022 Mar; 52(3):e13650. PubMed ID: 34291454 [TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Scorletti E; Byrne CD Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644 [TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128 [TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. de Castro GS; Calder PC Clin Nutr; 2018 Feb; 37(1):37-55. PubMed ID: 28139281 [TBL] [Abstract][Full Text] [Related]
14. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388 [TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. Chen LH; Wang YF; Xu QH; Chen SS Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302 [TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599 [TBL] [Abstract][Full Text] [Related]
17. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
18. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome. Pacifico L; Giansanti S; Gallozzi A; Chiesa C Mini Rev Med Chem; 2014; 14(10):791-804. PubMed ID: 25307311 [TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Spooner MH; Jump DB Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174 [TBL] [Abstract][Full Text] [Related]